Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vertigoheel is a multi-component homeopathic medicinal product developed for the treatment of vertigo of various origins. It is a fixed-dose combination consisting of four active ingredients: *Ambra grisea* (ambergris), *Anamirta cocculus* (Indian berry), *Conium maculatum* (hemlock), and *Petroleum rectificatum* (rectified petroleum). The drug is primarily used to reduce the frequency, intensity, and duration of vertigo attacks associated with conditions such as Meniere's disease, bilateral vestibulopathy, functional dizziness, and atherosclerosis-related vertigo. Its pharmacological profile includes the stimulation of cyclic nucleotide pathways (adenylate cyclase) and the inhibition of phosphodiesterase 5 (PDE5), which collectively promote vasorelaxation and improve microcirculatory perfusion in the inner ear and vertebrobasilar system. Recent preclinical research has also explored its potential as a cognitive enhancer, showing improvements in spatial and visual recognition memory in rodent models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vertigoheel.